Effect of acarbose, an alpha-glucosidase inhibitor
, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea.
The alpha-glucosidase inhibitor
l-blocks human immunodeficiency virus envelope glycopro-tein-mediated membrane fusion at the CXCR4 binding step.
The Newest Oral Agents: Alpha-Glucosidase Inhibitors
The Role of Alpha-Glucosidase Inhibitors
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor
to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data.
In patients with type 1 diabetes, insulin is used, whereas in patients with type 2 diabetes, sulfonylurea, biguanides, meglitinides, dipeptidyl-peptidase-4 (DPP-4) inhibitors, alpha-glucosidase inhibitors
, sodium glucose cotransporter 2 inhibitors (SGLT2), and glucagon-like peptide-1 (GLP-1) agonist are used.
(AGIs), such as acarbose (Precose) and miglitol (Glyset), block the absorption of ingested carbohydrates in the small intestine.
There are seven pharmacologic subclasses of oral antidiabetic agents: alpha-glucosidase inhibitors
, biguanides, dipeptidyl peptidase-4 inhibitors, meglitinides, sulfonylureas, sodium-glucose cotransporter-2 inhibitors, and thiazolidinediones.
The greatest compliance was observed with alpha-glucosidase inhibitors
(100%) and meglitinides (100%); nonetheless, only 5 participants used these drugs.
Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy Metformin, Alpha-Glucosidase Inhibitors
, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
Lebovitz, Alpha-Glucosidase Inhibitors
Keywords: Alpha-glucosidase inhibitors
, DPP4 inhibitors, GLP1 receptor agonists, Metformin, Pioglitazone, Pramlintide, SGLT2 inhibitors.
Both dipeptidyl peptidase-4 (DPP-4) inhibitors and alpha-glucosidase inhibitors
(AGIs) appear to be weight-neutral or to induce minimal changes in weight.
The global diabetes drugs and devices market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (insulin derivatives - short-acting, intermediate-acting, long-acting, premixed, and rapid-acting insulin; oral anti-diabetes drugs - alpha-glucosidase inhibitors
, biguanides, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylureas, thiazolidinediones; and non-insulin injectable anti-diabetes drugs - GLP-1 analogs), device type (diabetes monitoring and diagnostic devices - analog glucose meter, continuous glucose monitoring devices, glucose test strips, lancets and lancing devices; insulin delivery devices - insulin injectors, pens, pumps, syringes, etc.
Natural products as alpha-amylase and alpha-glucosidase inhibitors
and their hypoglycaemic potential in the treatment of diabetes: an update.